Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.

Kauf, Teresa L; Yang, Jui-Chen; Kimball, Alexa B.; Sundaram, Murali; Bao, Yanjun; Okun, Martin; Mulani, Parvez; Hauber, A. Brett; Johnson, F. Reed

doi:10.3109/09546634.2015.1034071

Record: found
Abstract: found
Article: not found

Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.

Author(s): Teresa L Kauf ¹ , Jui-Chen Yang ² , Alexa B Kimball ³ , Murali Sundaram ⁴ , Yanjun Bao ⁴ , Martin Okun ⁴ , Parvez Mulani ⁴ , A Brett Hauber ⁵ , F Reed Johnson ⁶

Publication date (Electronic): 2015

Journal: The Journal of dermatological treatment

Publisher: Informa UK Limited

Keywords: Benefit-risk, discrete-choice experiment, maximum acceptable risk, psoriasis, risk tolerance, tumor necrosis factor blocker

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Previous studies suggest that efficacy is more important than side-effect risks to psoriasis patients. However, those studies did not consider potentially fatal risks of biologic treatments.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Dermatolog Treat

Title: The Journal of dermatological treatment

Publisher: Informa UK Limited

ISSN (Electronic): 1471-1753

ISSN (Print): 0954-6634

Publication date (Electronic): 2015

Volume: 26

Issue: 6

Affiliations

[1 ] a Cubist Pharmaceuticals , Lexington , MA , USA .

[2 ] b Pacific Economics Research, LLC , Bellevue , WA , USA .

[3 ] c Massachusetts General Hospital , Boston , MA , USA .

[4 ] d AbbVie Inc . , North Chicago , IL , USA .

[5 ] e RTI Health Solutions, Research Triangle Park , NC , USA , and.

[6 ] f Center for Clinical and Genetic Economics, Duke Clinical Research Institute , Durham , NC , USA.

Article

DOI: 10.3109/09546634.2015.1034071

PubMed ID: 25946139

SO-VID: a716a547-4806-4b0b-b575-2bda8fd939c4

History

Keywords: risk tolerance,Benefit-risk,discrete-choice experiment,maximum acceptable risk,psoriasis,tumor necrosis factor blocker

Data availability:

Keywords: risk tolerance, Benefit-risk, discrete-choice experiment, maximum acceptable risk, psoriasis, tumor necrosis factor blocker

Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.

Read this article at

Abstract

Related collections

Efficacy of Communicating Science

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 258

Cited by 7